CIK 0001479290
RVNC Revance Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Feb 6, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
7
with a Form 4 at this company
Signals
Open-market buys and sells at Revance Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | David Hollander CMO & Global Therapeutics Lead sell | $16k 3,908 shares | -4% | - |
Transactions
The last 20 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 4, 2025 | Carey OConnor Kolaja director | UTender of shares Common Stock | -16,561 | $3.65 | $60k | 15,000 | Feb 6, 2025 |
| Feb 4, 2025 | Erica Jordan Chief Commercial Officer | UTender of shares Common Stock | -6,922 | $3.65 | $25k | 107,942 | Feb 6, 2025 |
| Feb 4, 2025 | David Hollander CMO & Global Therapeutics Lead | UTender of shares Common Stock | -9,733 | $3.65 | $36k | 95,212 | Feb 6, 2025 |
| Feb 4, 2025 | Julian S Gangolli director | UTender of shares Common Stock | -30,106 | $3.65 | $110k | 15,000 | Feb 6, 2025 |
| Feb 4, 2025 | Mark J Foley President & CEO | UTender of shares Common Stock | -996,935 | $3.65 | $3.6M | 27,933 | Feb 6, 2025 |
| Feb 4, 2025 | Vlad Coric director | UTender of shares Common Stock | -5,784 | $3.65 | $21k | 15,000 | Feb 6, 2025 |
| Feb 4, 2025 | Jill Beraud director | UTender of shares Common Stock | -28,606 | $3.65 | $104k | 15,000 | Feb 6, 2025 |
| Feb 6, 2025 | Vlad Coric director | DDisposition to issuer Common Stock | -15,000 | - | - | 0 | Feb 6, 2025 |
| Feb 4, 2025 | Mark J Foley President & CEO | UTender of shares Common Stockindirect: See footnote | -110,913 | $3.65 | $405k | 0 | Feb 6, 2025 |
| Feb 6, 2025 | Carey OConnor Kolaja director | DDisposition to issuer Common Stock | -15,000 | - | - | 0 | Feb 6, 2025 |
| Feb 6, 2025 | Erica Jordan Chief Commercial Officer | DDisposition to issuer Common Stock | -107,942 | - | - | 0 | Feb 6, 2025 |
| Feb 6, 2025 | David Hollander CMO & Global Therapeutics Lead | DDisposition to issuer Common Stock | -95,212 | - | - | 0 | Feb 6, 2025 |
| Feb 6, 2025 | Julian S Gangolli director | DDisposition to issuer Common Stock | -15,000 | - | - | 0 | Feb 6, 2025 |
| Feb 6, 2025 | Jill Beraud director | DDisposition to issuer Common Stock | -15,000 | - | - | 0 | Feb 6, 2025 |
| Feb 6, 2025 | Mark J Foley President & CEO | DDisposition to issuer Common Stock | -27,933 | - | - | 0 | Feb 6, 2025 |
| Feb 6, 2025 | Mark J Foley President & CEO | AGrant or award Common Stock | +84,686 | $0.00 | $0 | 84,686 | Feb 6, 2025 |
| Feb 6, 2025 | Mark J Foley President & CEO | DDisposition to issuer Common Stock | -84,686 | - | - | 0 | Feb 6, 2025 |
| Feb 3, 2025 | Mark J Foley CEO | AGrant or award Common Stock | +27,933 | $0.00 | $0 | 1,024,868 | Feb 5, 2025 |
| Dec 31, 2024 | Mark J Foley CEO | AGrant or award Common Stock | +1,000 | $2.18 | $2,185 | 996,935 | Jan 3, 2025 |
| Nov 18, 2024 | David Hollander CMO & Global Therapeutics Lead | SOpen-market sale Common Stock | -3,908 | $4.17 | $16k | 104,945 | Nov 19, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Jill Berauddirector
- Vlad Coricceo, officer, director
- Mark J FoleyPresident & CEO
- Julian S Gangollidirector
- David HollanderCMO & Global Therapeutics Lead
- Erica JordanChief Commercial Officer
- Carey OConnor Kolajadirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.